Baseline quality of life (QOL) as a predictor of stopping chemotherapy early, and of overall survival, in platinum-resistant/refractory ovarian cancer (PRROC): The GCIG symptom benefit study (SBS).

5508Background: 110 (19%) of the 570 women with PRROC enrolled in SBS stopped chemotherapy within 8 weeks. We sought to identify baseline characteristics, including QOL and clinical factors, that w...